알테오젠

196170KOSDAQ자연과학 및 공학 연구개발업

56.9 / 100

Reference Date: 2026-06-10

Financial Score26.5 / 40

News Sentiment16.4 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and ROE is above the industry average is also solid. Declined 8.4% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Alteogen is a biotech company leveraging platform technologies like Hybrozyme™, NexP™, and NexMab™ to develop and commercialize biopharmaceuticals, with licensing agreements with global pharma firms such as MSD and AstraZeneca, ensuring sustainable revenue through upfront fees, milestones, and royalties. Its key product ALT-B4 offers subcutaneous injection advantages over IV formulations, while its biosimilar business collaborates with Qilu Pharmaceutical to expand market reach.

Number of Employees

161people

Average Salary

149.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

123.07Industry Average 62.701.5Point

2.0x industry avg (risky)

PBR

—Industry Average 3.243.5Point

ROE

39.85Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

1.02Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲58.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲340.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 22.1% (improving, 3yr)

Detailed News Sentiment

46 totalPositive 14Neutral 15Negative 17Average Sentiment Score 65.7

Positive
알테오젠, ALT-B4 물질특허 유럽 허여…주가 급등
알테오젠의 ALT-B4 특허 유럽 등록으로 주가가 급등했다.
Positive
특허·마일스톤·코스피 이전까지…알테오젠에 쌓이는 기대
알테오젠의 유럽 ALT-B4 특허 등록 완료로 인해 피하주사 기술의 상업화 가능성이 높아져 긍정적인 시장 반응을 이끌고 있다.
Negative
‘검은 월요일’ 코스피 8.3%↓ 7500선도 내줬다
국내 주식시장의 큰 하락으로 알테오젠을 포함한 관련 종목들의 주가가 크게 하락했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 326,500Won52-week high 559,00052-week low 325,000

1-month return1.0Point

1m -8.42% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항 (아이젠피주(ALT-L9, 아일리아 바이오시밀러) 식약처 품목허가 승인)2026-05-15
Neutral분기보고서 (2026.03)2026-05-15